ArticleInternational journal of clinical and experimental medicine2015
Rs5498 polymorphism may be a risk factor for coronary heart disease in Chinese population: evidence from a meta-analysis involving 5537 subjects.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
- Association of ICAM-1 Gene Polymorphisms with Diabetic Retinopathy in T2DM Patients from Northern India: Case-control and meta-analysis.World journal of diabetes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite large numbers of studies from Chinese population related to the association between rs5498 polymorphism and coronary heart disease (CHD) risk, the results are inconsistent probably due to the difference in the nationalities. To further evaluate the impact of the rs5498 polymorphism on CHD risk of different nationalities population, we performed this meta-analysis. We comprehensively searched the eligible studies for the present meta-analysis through China National Knowledge Infrastructure (CNKI), PubMed, EMBASE databases. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were obtained to evaluate the strength of the association between rs5498 polymorphism and CHD risk. Finally, a total of 18 studies including 5537 subjects met the inclusion criteria. The pooled result showed that the rs5498 polymorphism was significantly associated with an increased risk of CHD in allele comparison model (OR=1.43, 95% CI=1.17-1.73, P=0.000), homozygote model (OR=1.23, 95% CI=1.03-1.46, P=0.000), heterozygote model (OR=1.23, 95% CI=1.03-1.46, P=0.018), dominant model (OR=1.45, 95% CI=1.21-1.74, P=0.001) and recessive model (OR=2.17, 95% CI=1.70-2.77, P=0.002). But subgroup analysis only supported the results from data of Han and Zhuang population in South China and North China. We did not find any evidences revealing some relationship between them in the Uygur population of Northwest China. Totally, the results of our meta-analysis indicate that the rs5498 polymorphism may be associated with coronary heart disease in Han and Zhuang population but not in Uyghur population. A large number of well-designed and multiracial studies should be conducted to re-evaluate the relationship.
Indexed as
Identifiers
26770336PMC4694236W2409829288What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.